Evidence map›Paper›PMID 39434151›Full record

ArticleFluids and barriers of the CNS2024

Data-independent acquisition proteomic analysis of the brain microvasculature in Alzheimer's disease identifies major pathways of dysfunction and upregulation of cytoprotective responses.

Michelle A Erickson, Richard S Johnson, Mamatha Damodarasamy, Michael J MacCoss, C Dirk Keene, William A Banks, May J Reed

Abstract read
In one paragraph

Article in Fluids and barriers of the CNS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Michelle A EricksonDepartment of Medicine, Division of Gerontology and Geriatric Medicine, University of Washington, Harborview Medical Center, 325 9th Avenue, Seattle, WA, 98104, USA. mericks9@uw.edu.
Richard S JohnsonDepartment of Genome Sciences, University of Washington, Seattle, USA.
Mamatha DamodarasamyDepartment of Medicine, Division of Gerontology and Geriatric Medicine, University of Washington, Harborview Medical Center, 325 9th Avenue, Seattle, WA, 98104, USA.
Michael J MacCossDepartment of Genome Sciences, University of Washington, Seattle, USA.
C Dirk KeeneDepartment of Laboratory Medicine and Pathology, Division of Neuropathology, University of Washington, Seattle, WA, USA.
William A BanksDepartment of Medicine, Division of Gerontology and Geriatric Medicine, University of Washington, Harborview Medical Center, 325 9th Avenue, Seattle, WA, 98104, USA.
May J ReedDepartment of Medicine, Division of Gerontology and Geriatric Medicine, University of Washington, Harborview Medical Center, 325 9th Avenue, Seattle, WA, 98104, USA. mjr@uw.edu.

Funding

University of Washington Alzheimer's Disease Research CenterP30AG066509 · NIA · UNIVERSITY OF WASHINGTON · PI Amanda D. Boyd · 2020 to 2026
$29.0M
Project 4: Novel reagent development to enable molecular characterizationU19AG065156 · NIA · UNIVERSITY OF WASHINGTON · PI TIAN, LU · 2020 to 2024
$15.9M
Amyloid Beta and Collagen IV Interactions in the Brain Microvasculature in Alzheimers DiseaseR01AG087226 · NIA · UNIVERSITY OF WASHINGTON · PI MAY J REED · 2024 to 2026
$1.9M
Viable Microvessels for the Study of the Microvasculature in Alzheimer's DiseaseR21AG073676 · NIA · UNIVERSITY OF WASHINGTON · PI REED, MAY J · 2021 to 2022
$428k
The Microvasculature in Alzheimer’s Disease: Viable Microvessels for Studies of Brain Endothelial and Glycocalyx HealthR03AG075397 · NIA · UNIVERSITY OF WASHINGTON · PI REED, MAY J · 2022 to 2022
$156k
The Brain Microvasculature, Hyaluronan, and AgingR03AG051071 · NIA · UNIVERSITY OF WASHINGTON · PI REED, MAY J · 2015 to 2016
$155k
NIA NIH HHS P30 AG066509NIA NIH HHS R01 AG087226NIA NIH HHS R03 AG075397NIA NIH HHS R21 AG073676NIH HHS P30AG066509NIH HHS R03AG051071NIH HHS U19AG065156
6 · The paper itself

Abstract

Brain microvascular dysfunction is an important feature of Alzheimer's disease (AD). To better understand the brain microvascular molecular signatures of AD, we processed and analyzed isolated human brain microvessels by data-independent acquisition liquid chromatography with tandem mass spectrometry (DIA LC-MS/MS) to generate a quantitative dataset at the peptide and protein level. Brain microvessels were isolated from parietal cortex grey matter using protocols that preserve viability for downstream functional studies. Our cohort included 23 subjects with clinical and neuropathologic concordance for Alzheimer's disease, and 21 age-matched controls. In our analysis, we identified 168 proteins whose abundance was significantly increased, and no proteins that were significantly decreased in AD. The most highly increased proteins included amyloid beta, tau, midkine, SPARC related modular calcium binding 1 (SMOC1), and fatty acid binding protein 7 (FABP7). Additionally, Gene Ontology (GO) enrichment analysis identified the enrichment of increased proteins involved in cellular detoxification and antioxidative responses. A systematic evaluation of protein functions using the UniProt database identified groupings into common functional themes including the regulation of cellular proliferation, cellular differentiation and survival, inflammation, extracellular matrix, cell stress responses, metabolism, coagulation and heme breakdown, protein degradation, cytoskeleton, subcellular trafficking, cell motility, and cell signaling. This suggests that AD brain microvessels exist in a stressed state of increased energy demand, and mount a compensatory response to ongoing oxidative and cellular damage that is associated with AD. We also used public RNAseq databases to identify cell-type enriched genes that were detected at the protein level and found no changes in abundance of these proteins between control and AD groups, indicating that changes in cellular composition of the isolated microvessels were minimal between AD and no-AD groups. Using public data, we additionally found that under half of the proteins that were significantly increased in AD microvessels had concordant changes in brain microvascular mRNA, implying substantial discordance between gene and protein levels. Together, our results offer novel insights into the molecular underpinnings of brain microvascular dysfunction in AD.

Indexed as

Alzheimer DiseaseBrainMicrovesselsProteomicsAgedAged, 80 and overChromatography, LiquidCohort StudiesFemaleHumansMaleMiddle AgedTandem Mass SpectrometryUp-RegulationAlzheimer’s diseaseBlood–brain barrierBrain microvesselsNeurovascular unitProteomics

Identifiers

PMID39434151
PMCPMC11492478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.